




AU9510303

(12) PATENT ABRIDGMENT (11) Document No. AU-B-10303/95
(19) AUSTRALIAN PATENT OFFICE (10) Acceptance No. 673785

- (54) Title
PYRIMIDINE CYANOGUANIDINES AS K-CHANNEL BLOCKERS
- International Patent Classification(s)
(51)⁵ **C07D 239/42 A61K 031/505**
- (21) Application No. : **10303/95** (22) Application Date : **26.11.93**
- (87) PCT Publication Number : **WO94/29280**
- (30) Priority Data
- (31) Number (32) Date (33) Country
US 9305458 11.06.93 WO WORLD INTELLECTUAL PROPERTY ORGANIZATION (WIPO)
- (43) Publication Date : **03.01.95**
- (44) Publication Date of Accepted Application : **21.11.96**
- (71) Applicant(s)
THE UPJOHN COMPANY
- (72) Inventor(s)
STEPHEN J HUMPHREY; KAUSHIK D. MEISHERI; JAMES R LUDENS; JACKSON B. HESTER JR.
- (74) Attorney or Agent
PHILLIPS ORMONDE & FITZPATRICK , 367 Collins Street, MELBOURNE VIC 3000
- (57) Claim

1. A compound of Formula I and its pharmaceutically acceptable acid addition salts



wherein

R₁ is hydrogen or methyl;

R₂ is C₁-C₆ alkyl, C₂-C₆ alkenyl, C₂-C₆ alkynyl, C₃-C₅ cycloalkyl, C₃-C₅ cycloalkenyl, hydroxy methyl, methoxy-C₁-C₅ alkyl, or R₁ and R₂ are combined to form a C₃-C₆ carbocyclic ring;

R₃ and R₄ are each independently selected to be hydrogen, C₁-C₄ alkyl, F, Cl, Br, I or CF₃;

R₅ is hydrogen, F or Cl;

R₆ is hydrogen, -NH₂, -NHCH₃, -NHC₂H₅, -NHCH(CH₃)₂, -N(CH₃)₂, -N(C₂H₅)₂, NH(CH₂)_m-OC₁-C₃ alkyl (where m is 2 or 3), -NHC(O)C₁-C₃ alkyl, Cl or Br; and n is 0 or 1.

6. A method for blocking a potassium channel pathway in living tissue of an animal comprising administering to an animal in need of such potassium channel blocking a therapeutic effective amount of a compound of Formula I or a pharmaceutically acceptable acid addition salt thereof.




AU9510303

(PCT)

(51) International Patent Classification ⁵ : C07D 239/42, A61K 31/505		(11) International Publication Number: WO 94/29280
A1		(43) International Publication Date: 22 December 1994 (22.12.94)
(21) International Application Number: PCT/US93/11332		TER, Jackson, B., Jr. [US/US]; 9219 East ML Avenue, Galesburg, MI 49053 (US).
(22) International Filing Date: 26 November 1993 (26.11.93)		(74) Agent: CORNEGLIO, Donald, L.; Corporate Intellectual Property Law, The Upjohn Company, 301 Henrietta Street, Kalamazoo, MI 49001 (US).
(30) Priority Data: PCT/US93/05458 11 June 1993 (11.06.93) WO (34) Countries for which the regional or international application was filed: US et al.		(81) Designated States: AT, AU, BB, BG, BR, BY, CA, CH, CZ, DE, DK, ES, FI, GB, HU, JP, KP, KR, KZ, LK, LU, LV, MG, MN, MW, NL, NO, NZ, PL, PT, RO, RU, SD, SE, SK, UA, US, UZ, VN, European patent (AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE). OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG).
(60) Parent Application or Grant (63) Related by Continuation US PCT/US93/05458 (CIP) Filed on 11 June 1993 (11.06.93)		
(71) Applicant (for all designated States except US): THE UPJOHN COMPANY [US/US]; 301 Henrietta Street, Kalamazoo, MI 49001 (US).		Published With international search report.
(72) Inventors; and (75) Inventors/Applicants (for US only): HUMPHREY, Stephen, J. [US/US]; 2670 Fairgrove, Kalamazoo, MI 49009 (US). MEISHERI, Kaushik, D. [US/US]; 416 Edgemoor Avenue, Kalamazoo, MI 49001 (US). LUDENS, James, R. [US/US]; 5129 Woodmont Drive, Kalamazoo, MI 49001 (US). HES-		

673/83

(54) Title: PYRIMIDINE CYANOGUANIDINES AS K-CHANNEL BLOCKERS



(57) Abstract

Pyrimidine-cyanoguanidine compounds of Formula (I) and its pharmaceutically acceptable acid addition salts wherein R₁ is hydrogen or methyl; R₂ is C₁-C₆ alkyl, C₂-C₆ alkenyl, C₂-C₆ alkynyl, C₃-C₅ cycloalkyl, C₃-C₅ cycloalkenyl, hydroxy methyl, methoxy C₁-C₅ alkyl, or R₁ and R₂ are combined to form a C₃-C₆ carbocyclic ring; R₃ and R₄ are each independently selected to be hydrogen, C₁-C₄ alkyl, F, Cl, Br, I or CF₃; R₅ is hydrogen, F or Cl; R₆ is hydrogen, -NH₂, -NHCH₃, -NHC₂H₅, -NHCH(CH₃)₂, -N(CH₃)₂, -N(C₂H₅)₂, NH(CH₂)_m-OC₁-C₃ alkyl (where m is 2 or 3), -NHC(OC₁-C₃ alkyl, Cl or Br; and n is 0 or 1. The compounds of Formula I are potassium channel blockers useful in the treatment of cardiovascular disorders such as congestive heart failure and hypertension and as a diuretic.

-1-

PYRIMIDINE, CYANO GUANIDINES AS K-CHANNEL BLOCKERS
BACKGROUND OF THE INVENTION

The present invention is directed toward pyrimidine-cyanoguanidine compounds which are potassium channel blockers useful in the treatment of cardiovascular disorders such as congestive heart failure and hypertension. The pyrimidine-cyanoguanidine compounds of this invention, unlike other cyanoguanidines, block potassium channel conduction in vascular smooth muscle and in ATP-sensitive potassium channels in apical membranes of the kidney.

It is known that K⁺ channels are important for regulating potassium excretion by the kidney and it has been proposed that inhibition of ATP-sensitive K⁺ channel conduction in apical cell membranes of the thick ascending limb of Henle's loop would reduce potassium recycling across the membrane and thus reduce sodium resorption *via* the Na⁺-2Cl⁻-K⁺ co-transporter. It has also been proposed that inhibition of the ATP-sensitive K⁺ channels of apical membranes in principal cells of the initial and cortical collecting tubule would reduce K⁺ secretion, the primary source of urinary potassium. K⁺ channel antagonist activities necessary to produce the observed eukalemic natriuresis have been documented in the rat kidney.

The subject compounds are effective blockers for the ATP-sensitive potassium channels of the thick ascending limb of Henle's loop and the principal cells of the initial and cortical collecting tubules of the kidney. This activity results in an enhanced urinary excretion of sodium and water without enhanced potassium excretion. This provides a useful diuresis which is not complicated by an undesirable reduction in plasma potassium levels or hypokalemia.

Thus, the subject series of cyanoguanidines, although very closely related to the K⁺ channel agonist pinacidil and related compounds, are potent K⁺ channel antagonists.

INFORMATION DISCLOSURE STATEMENT

U.S. Patent 4,057,636 discloses pyridylguanidine compounds structurally similar to the subject compounds except that the subject compounds have a branched methylene linking group to a phenyl which can be optionally substituted. Surprisingly, the subject compounds are potassium channel blockers whereas the compounds of 4,057,636 are potassium channel openers.

Pinacidil, its pyridine N-oxide and related pyridylcyanoguanidines are a class of compounds structurally related to the subject invention. Articles disclosing these compounds are as follows: Smallwood, JK, **J. Card. Pharm.**, 12:102-9 (1988); and Peterson, HJ, **J. Med. Chem.**, 21(8):773-81 (1978).

Other publications include, JP 166119, published January 2, 1991, discloses cyanoguanidine derivatives have a branched alkyl group at the C-1 position but no phenyl group attached thereto. GB 055209, December 20, 1974, Leo Pharmaceutical, discloses N-cyano-N'-pyridyl guanidine as hypotensives.

European Patent Application 92104287.5 discloses compounds having a pyridine N-oxide and amine substitutions although not linked to a phenyl.


The state of the art on potassium channel mechanisms and pinacidil is discussed in **Annual Reports in Medicinal Chemistry**, Robertson DW, et al., 24, Ch 10, 91-100 (1989).

5

SUMMARY OF THE INVENTION

In one aspect the present invention is a compound of Formula I and its pharmaceutically acceptable acid addition salts

10



15

wherein

R₁ is hydrogen or methyl;

R₂ is C₁-C₆ alkyl, C₂-C₆ alkenyl, C₂-C₆ alkynyl, C₃-C₅ cycloalkyl, C₃-C₅ cycloalkenyl, hydroxymethyl, methoxy-C₁-C₃ alkyl, or R₁ and R₂ are combined to form a C₃-C₆ carbocyclic ring;

R₃ and R₄ are each independently selected to be hydrogen, C₁-C₄ alkyl, F, Cl, Br, I or CF₃;

R₅ is hydrogen, F or Cl.

R₆ is hydrogen, -NH₂, -NHCH₃, -NHC₂H₅, -NHCH(CH₃)₂, -N(CH₃)₂, -N(C₂H₅)₂, -NH(CH₂)_m-OC₁-C₃alkyl (where m is 2 or 3), -NHC(O)C₁-C₃alkyl, Cl or Br; and n is 0 or 1.

In another aspect, the subject invention is useful as a potassium channel blocker and can be used in the treatment of cardiovascular disorders such as congestive heart failure, hypertension and shock.

Throughout the description and claims of this specification, the word "comprise" and variations of the word, such as "comprising" and "comprises", is not intended to exclude other additives, components, integers or steps.


DETAILED DESCRIPTION OF THE INVENTION

The present invention is directed toward compounds of Formula I and its pharmaceutically acceptable acid addition salts, as structurally depicted above. The compounds of Formula I include both enantiomers as well as salts and tautomeric forms.



Preferably, at least one substituent is present on the benzylic carbon and when only one alkyl substituent is present the activity resides with the (R) enantiomer. Particularly preferred are compounds with small cycloalkyl, alkyl or R_1R_2 carbocyclic substituents on the benzylic carbon and with the 3-chloro or 3-fluoro substituent on the
5 phenyl ring.

Pharmaceutically acceptable acid addition salts of the Formula I, may be chosen from the



following: acetate, adipate, alginate, aspartate, benzoate, benzenesulfonate, bisulfate, butyrate, citrate, camphorate, camphorsulfonate, cyclopentanepropionate, digluconate, dodecylsulfate, ethanesulfonate, fumarate, glucoheptanoate, glycerophosphate, hemisulfate, heptanoate, hexanoate, hydrochloride, hydrobromide, hydroiodide, 2-hydroxyethanesulfonate, lactate, maleate, methanesulfonate, 2-naphthalenesulfonate, nicotinate, oxalate, pamoate, pectinate, persulfate, 3-phenylpropionate, picrate, pivalate, propionate, succinate, tartrate, thiocyanate, tosylate, and undecanoate.

The carbon content of various hydrocarbon-containing moieties is indicated by a prefix designating the minimum and maximum number of carbon atoms in the moiety, i.e., the prefix C_i-C_j indicates a carbon atom's content of the integer "i" to the integer "j" carbon atoms, inclusive. For example, C₁-C₃ alkyl refers to alkyl of 1-3 carbon atoms, inclusive, or methyl, ethyl, propyl, and isopropyl, and isomeric forms thereof.

C₃-C₅ cycloalkyl is cyclopropane, cyclobutane, cyclopentane and isomeric forms thereof.

A "C₃-C₆ carbocyclic ring" means cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cyclobutenyl, cyclopentenyl or cyclohexenyl.

The compounds of Formula I will thus be useful for treating cardiovascular disorders such as congestive heart failure and forms of hypertension that can benefit from a reduction in plasma fluid volume. In addition, the compounds of this invention, by virtue of their potassium channel blocking activity, will be useful for preventing the undesirable increase in plasma renin activity that might be expected to result from a reduction of plasma fluid volume or from reductions in blood pressure by other co-administered antihypertensive agents. This activity will enhance the antihypertensive activities of both agents.

This invention thus contemplates the co-administration of compounds of Formula I with other antihypertensive agents such as the ACE inhibitors, the β -adrenergic blockers, the α_1 -adrenergic blockers, the α_2 -adrenergic agonists, calcium channel blockers, and other vasodilators such as the nitrates and hydralazine, etc. In addition, the compounds of Formula I are useful for their antiarrhythmic activity and their ability to antagonize overdoses of potassium channel agonists, to prevent excessive hair growth, to increase insulin release, to treat shock, to control reflex hyperemia and to reduce body weight.

The enantiomers of the compounds of Formula I in which R₁ and R₂ are different are considered to be important variations of this invention. When R₁ is hydrogen and R₂ is alkyl the preferred enantiomer has the (R) absolute configuration. Also important are the pharmacologically acceptable acid addition salts, the pharmaceutical preparations for oral, transdermal and parenteral administration and the novel chemical intermediates and processes for the preparation of the compounds of Formula I.

The compounds can be administered intravenously, intramuscularly, topically, transdermally

such as by skin patches, buccally, suppositorially or orally to man or other animals. The compositions of the present invention can be presented for administration to humans and animals in unit dosage forms, such as tablets, capsules, pills, powders, granules, sterile parenteral solutions or suspensions, oral solutions or suspensions, oil in water and water in oil emulsions containing
5 suitable quantities of the compound, suppositories and in fluid suspensions or solutions.

For oral administration, either solid or fluid unit dosage forms can be prepared. For preparing solid compositions such as tablets, the compound can be mixed with conventional ingredients such as talc, magnesium stearate, dicalcium phosphate, magnesium aluminum silicate, calcium sulfate, starch, lactose, acacia, methylcellulose, and functionally similar materials as pharmaceutical diluents
10 or carriers. Capsules are prepared by mixing the compound with an inert pharmaceutical diluent and filling the mixture into a hard gelatin capsule of appropriate size. Soft gelatin capsules are prepared by machine encapsulation of a slurry of the compound with an acceptable vegetable oil, light liquid petrolatum or other inert oil.


Fluid unit dosage forms for oral administration such as syrups, elixirs, and suspensions can be
15 prepared. The forms can be dissolved in an aqueous vehicle together with sugar, aromatic flavoring agents and preservatives to form a syrup. Suspensions can be prepared with an aqueous vehicle with the aid of a suspending agent such as acacia, tragacanth, methylcellulose and the like.

For parenteral administration, fluid unit dosage forms can be prepared utilizing the compound and a sterile vehicle. In preparing solutions the compound can be dissolved in water for injection
20 and filter sterilized before filling into a suitable vial or ampoule and sealing. Adjuvants such as a local anesthetic, preservative and buffering agents can be dissolved in the vehicle. The composition can be frozen after filling into a vial and the water removed under vacuum. The dry lyophilized powder can then be sealed in the vial and reconstituted prior to use.

As diuretic agents the compounds of Formula I can be used in unit dosages of 1 to 1000 mg
25 in oral or injectable preparations.

CHEMISTRY


The subject compounds were prepared by the successive reaction of two amines with diphenyl cyanocarbonimidate (i). The first reaction was normally carried out with one



35 equivalent of the less reactive amine in Et₂O or ethylene glycol dimethyl ether. In some cases, however, this procedure was unsuccessful and other solvents or conditions were required. For 5-

pyrimidyl, where R in the above reaction scheme is 5-pyrimidyl, for example, it was necessary to warm the mixture of i and the amine to 50 °C in dimethoxyethane (DME). In the second step the second amine was usually allowed to react with ii in refluxing isopropanol or 1,4-dioxane. Other solvents such as dimethylformamide are also suitable for this reaction. This reaction required either two equivalents of the amine or one equivalent of the amine when an excess of N-methylmorpholine was employed.

Table I. Physical and Analytical Data for the Cyanoguanidines of Formula I



Example #	R ₁	R ₂	Z	R ₆	mp, °C	Recryst. Solvent
1*	H	CH ₃	Ph	H	203-204	EtOAc
2	-CH ₂ -CH ₂ -CH ₂ -		Ph	NH ₂	252-253(dec)	MeOH

* (R) Enantiomer.

Compounds of the subject invention were tested for diuretic effect as well as potassium channel blocking activity.

The results for potassium channel blocking were obtained by using isolated rabbit mesenteric artery (RMA) procedures. Norepinephrine (5 µM) was used to contract the RMA rings twice, with an hour separating the two contractions. During this hour the tissues equilibrated in physiological salt solution at a resting tension of 1 gram. Upon the plateau of the second contraction 1 µM pinacidil was added to all tissues and the resulting relaxation time course was studied for thirty minutes. Pinacidil at this concentration has been shown to produce maximal K⁺ channel dependent vasodilation in the system. By studying the ability of the test compounds to inhibit this pinacidil-induced relaxation, the degree of potassium antagonism could be determined. The compounds were applied to the tissues for one hour between the two contractions and the pinacidil-induced relaxation was studied in the continuing presence of the compounds. Thus, the total time of pretreatment with the test compound was 75 minutes before the addition of pinacidil. Only one tissue was used per concentration of each compound, and in the case of no relaxation, the tissues were shown to be

capable of relaxation by known vasodilators. The compounds were tested at 5 μ M. The inhibitory effect of a compound was measured as percent inhibition of pinacidil relaxation at 15 minutes in comparison with the control.

The diuretic activity was determined in female Harlan Sprague-Dawley rats weighing 200 to 230 grams that were fasted 15 hours overnight, and then were deprived of both food and water for an additional hour prior to dosing. Table II shows the measurement of net increase (above control) in urinary Na^+ excretion (μEq) for a 5 hour test period divided by the total of the three drug doses (mg/kg) administered IP in the diuretic screen. It approximates the area under the dose response curve. The vehicle was 20% dimethylacetamide (DMA; v/v) in a pH 7.4 phosphate buffer (0.58% Na_2HPO_4 and 0.13% $\text{NaH}_2\text{PO}_4 \cdot \text{H}_2\text{O}$). Sufficient drug was suspended in 1 to 2 ml of this vehicle to deliver doses of 1.0 to 30 mg/kg in a volume of 0.5 ml (2-4 rats/dose). At least 2 vehicle control rats, and, for most tests, 2 standard diuretic treated rats were included in each experiment. Standards used as comparators included the K^+ retaining diuretic amiloride and the K^+ wasting diuretics furosemide, hydrochlorothiazide and metolazone.

Following their IP doses, the rats' urinary bladders were gently compressed to eliminate all pretreatment urine, and two identically treated rats were placed in a stainless steel metabolism cage equipped with a graduated test tube to collect voided urine. At 2 and 5 hours post treatment, the rats' bladders were again compressed, the volume of urine excreted by the pair of rats was recorded, and aliquots of urine were retained for analysis of Na^+ and K^+ concentrations with a NOVA-13 selective ion analyzer. Following the 5 hour urine collection, the rats were returned to their stock cages, and at least 1 week of recovery was allowed between a maximum of 3 diuretic tests.

The electrolyte concentrations detected in these urine samples were manually multiplied by their respective volumes to determine total milliequivalent (mEq) excretion of Na^+ and K^+ per pair of rats, and the results obtained with multiple racks per drug treatment were averaged. Increases in urinary Na^+ excretion of 50% or more above the pooled control tests were regarded as reflecting activity.

Data for K^+ channel antagonist activity on rabbit mesenteric artery (RMA) and natriuretic efficacy after intraparenteral (IP) administration to rats are collected in Table II.

Table II. Natriuretic and Vascular Potassium Channel Antagonist Activities for the Compounds in Table I.

Compound Example 77#	RMA K ⁺ Channel Antagonism % I at 5 μ M ^a	5 h Net Natriuretic Efficacy (μ Eq Na ⁺ /mg/kg) ^c
Control*	0.0 $\pm$ 0.0 (2) ^b	0.0
Pinacidil**	0.0 (1)	-60 ^d
1	81.7 $\pm$ 4.4 (3)	13.2
2	97	43

Notes for Table II

- * Not a compound of the subject invention; R of Formula iii is 3-pyridyl, R₁ and R₂ are H and R₃ is CH(Ph)₂.
- ** Not a compound of the subject invention.
- a. This is a measure of a compound's ability to inhibit the relaxation of norepinephrine (5 μ M) contracted rabbit mesenteric artery rings by pinacidil (1 μ M). It is expressed as percent inhibition (mean $\pm$ sem) at an inhibitor concentration of 5 μ M. Compounds with 65% or greater inhibition at 5 μ M are considered to be active, with 20-65% inhibition moderately active and with less than 20% inhibition inactive.
- b. Number of mesenteric rings used for the determination.
- c. This represents the net increase (above control) in urinary Na⁺ excretion (μ Eq) for the 5 hour test period divided by the total of the three drug doses (mg/kg) administered IP in the stage II diuretic screen in rats. It approximates the area under the dose response curve.
- d. Antidiuresis seen with 5 mg/kg oral dosage. Similar responses have been obtained with IP and IV administration.

Table II shows that the compounds of the invention have good potassium channel antagonist activity as well as natriuretic activity.

Example 1: (R)-N''-Cyano-N-(5-pyrimidyl)-N'-(1-phenyl)ethylguanidine

A stirred mixture of diphenyl cyanocarbonimidate (1.05 g, 0.00442 mol), 5-amino-pyrimidine (0.42 g, 0.00442 mol) and Et₂O (15 mL) was kept at ambient temperature for 4 days and at reflux for one day. There was little reaction. The solvent was evaporated and the residue was mixed with DME and warmed at 50-55° for 2 days. The mixture was cooled, diluted with Et₂O and filtered; the solid was washed with Et₂O and dried to give 0.57 g of N'-Cyano-N-(5-pyrimidyl)-O-phenylisourea product.

A stirred mixture of N'-cyano-N-(5-pyrimidyl)-O-phenylisourea (0.5 g, 0.00209 mol), (R)- α -methylbenzylamine (1.0 mL) and DMF (4 mL) was kept, under nitrogen, at ambient temperature for 18 hours and concentrated *in vacuo*. The residue was allowed to crystallize from EtOAc-*tert*-butyl methyl ether. The solid was triturated with Et₂O and *tert*-butyl methyl ether and crystallized from EtOAc to give product: NMR (CDCl₃) δ 1.61 (d, 3 H), 4.92 (m, 1 H), 6.05 (broad s, 1 H), 7.38 (m, 6 H), 8.56 (s, 2 H), 8.97 (s, 1 H); IR (Nujol) 3262, 3109, 3054, 2174, 1600, 1570 cm⁻¹; MS m/z (relative intensity) 266 (M⁺, 100), 251 (24.3), 161 (4.0), 146 (33.0), 120 (40.5), 105 (100).


Example 2: N-(2-Amino-5-pyrimidyl)-N''-cyano-N'-(1-phenyl)cyclobutylguanidine

A stirred mixture of 2,5-diaminopyrimidine [Raiziss, G.W. and Freifelder, M., J. Am. Chem. Soc., 64:2340 (1942)] (0.65 g, 5.9 mmol) and ethylene glycol dimethyl ether (10 ml), under nitrogen, was treated during 2 minutes with diphenyl cyanocarbonimidate (1.41 g, 5.9 mmol) and kept at ambient temperature (24°C) for 20 hours. It was then diluted with Et₂O and the resulting solid was collected by filtration, washed with Et₂O and dried to give 1.40 g (93%) of product, N-(2-amino-5-pyrimidyl)-N'-cyano-O-phenylisourea: mp 257-259°C; IR (Nujol) 2924, 2194, 1614, 1559 cm⁻¹; MS m/z (relative intensity) 254 (M⁺, 40.6), 161 (42.2), 118 (25.2), 94 (100); NMR [(CD₃)₂SO] δ 6.83 (s, 2H), 7.30 (m, 3H), 7.44 (m, 2H), 8.31 (s, 2H), 10.45 (broad s, 1H).

10 A stirred mixture of N-(2-amino-5-pyrimidyl)-N'-cyano-O-phenylisourea (1.2 g, 4.72 mmol), 1-amino-1-phenylcyclobutane (0.70 g, 4.77 mmol), 4-methylmorpholine (1.3 ml, 11.8 mmol) and 1,4-dioxane (25 ml) was refluxed, under nitrogen, for 24 hours and kept at ambient temperature for 24 hours. The resulting precipitate was collected by filtration and crystallized from acetonitrile to give 0.70 g (48.3%) of the titled product, mp 251-253°C (dec). The analytical sample was
15 recrystallized from methanol and had: mp 252-253°C (dec.); IR (Nujol) 3293, 2925, 2159, 1589, 1582, 1553 cm⁻¹; MS m/z (relative intensity) 307 (M⁺, 33.7), 279 (37.3), 160 (25.3), 120 (100); NMR [(CD₃)₂SO] δ 1.75 (m, 1H), 1.90 (m, 1H), 2.45 (m, 4H), 6.78 (s, 2H), 7.22 (m, 1H), 7.39 (m, 4H), 7.68 (s, 1H), 8.03 (s, 2H), 8.43 (s, 1H). Anal. Calc'd for C₁₆H₁₇N₇: C, 62.52; H, 5.58; N, 31.90. Found: C, 62.32; H, 5.45; N, 32.00.

The claims defining the invention are as follows:

1. A compound of Formula I and its pharmaceutically acceptable acid addition salts



wherein

- 10 R_1 is hydrogen or methyl;
 R_2 is C_1 - C_6 alkyl, C_2 - C_6 alkenyl, C_2 - C_6 alkynyl, C_3 - C_5 cycloalkyl, C_3 - C_5 cycloalkenyl, hydroxy methyl, methoxy- C_1 - C_5 alkyl, or R_1 and R_2 are combined to form a C_3 - C_6 carbocyclic ring;
 R_3 and R_4 are each independently selected to be hydrogen, C_1 - C_4 alkyl, F, Cl, Br, I or CF_3 ;
 R_5 is hydrogen, F or Cl;
 15 R_6 is hydrogen, $-NH_2$, $-NHCH_3$, $-NHC_2H_5$, $-NHCH(CH_3)_2$, $-N(CH_3)_2$, $-N(C_2H_5)_2$, $NH(CH_2)_m-OC_1-C_3$ alkyl (where m is 2 or 3), $-NHC(O)C_1-C_3$ alkyl, Cl or Br; and n is 0 or 1.
2. The compound of Claim 1 where R_1 and R_2 are joined to form cyclobutyl.
- 20 3. The compound of Claim 1 where R_1 is hydrogen and R_2 is ethyl.
4. The compound of any one of claims 1 to 3 where R_6 is NH_2 , $NHCH_3$ or NHC_2H_5 .
5. The compound of claim 1 which is
- 25 a) (R)-N'-'-Cyano-N-(5-pyrimidyl)-N'-(1-phenyl)ethylguanidine;
 b) N-(2-Amino-5-pyrimidyl)-N''-cyano-N'-(1-phenyl)cyclobutylguanidine.
6. A method for blocking a potassium channel pathway in living tissue of an animal comprising administering to an animal in need of such potassium channel blocking a therapeutic effective amount of a compound of Formula I or a pharmaceutically acceptable acid addition salt thereof.
- 30 7. A method of claim 6 wherein said animal is a human.
8. The method of claim 6 or 7 wherein the compound of Formula I is administered intravenously, intramuscularly, topically, transdermally, buccally, suppositorally, orally, or parenterally.



9. The method of any one of claims 6 to 8 wherein the compound is administered as a diuretic.

DATED: 5 March, 1996

5 PHILLIPS ORMONDE & FITZPATRICK

Attorneys for:

THE UPJOHN COMPANY

~~WINWORDIWENDY.TYPING10101T.DOC~~

INTERNATIONAL SEARCH REPORT

International application No.

PCT/US 93/11332

A. CLASSIFICATION OF SUBJECT MATTER
IPC 5 C07D239/42 A61K31/505

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 5 C07D

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	US,A,4 057 636 (LEO PHARMACEUTICAL PRODUCTS) 8 November 1977 cited in the application see table A, compounds in which R1 is alpha-methylbenzyl or alpha,alpha-dimethylbenzyl see column 3, line 14 - column 3, line 25 ---	1,6
A	US,A,5 006 523 (E.R. SQUIBB & SONS, INC.) 9 April 1991 see column 1,2 --- -/--	1,6

☒ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

* Special categories of cited documents :

- "A" document defining the general state of the art which is not considered to be of particular relevance
"E" earlier document but published on or after the international filing date
"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
"O" document referring to an oral disclosure, use, exhibition or other means
"P" document published prior to the international filing date but later than the priority date claimed

- "T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
"&" document member of the same patent family

Date of the actual completion of the international search

28 March 1994

Date of mailing of the international search report

5. 04. 94

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+ 31-70) 340-2040, Tx. 31 651 epo nl,
Fax (+ 31-70) 340-3016

Authorized officer

De Jong, B

INTERNATIONAL SEARCH REPORT

International application No.

PCT/US 93/11332

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	JOURNAL OF MEDICINAL CHEMISTRY vol. 21, no. 8 , 1978 , WASHINGTON US pages 773 - 781 H.J. PETERSEN 'Synthesis and hypotensive activity of N-alkyl-N''-cyano-N'-pyridyl- guanidines' cited in the application See table I, compounds 35,69 ---	1,6
A	EP,A,0 354 553 (E.R. SQUIBB & SONS, INC.) 14 February 1990 see page 2, lines 1-4; page8, lines 23-32 see example 11 ---	1,6
A	EP,A,0 381 504 (ELI LILLY AND COMPANY) 8 August 1990 ---	1,6
A	DE,A,30 05 786 (EISAI CO.) 28 August 1980 see page 26 -----	1,6

INTERNATIONAL SEARCH REPORT

International application No.

PCT/US 93/11332

Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This international search report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☐ Claims Nos.:
because they relate to subject matter not required to be searched by this Authority, namely:
Although claims 6-8 are directed to a method of treatment of (diagnostic method practised on) the human/animal body, the search has been carried out and based on the alleged effects of the compounds/composition.
2. ☐ Claims Nos.:
because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:
3. ☐ Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
☐ No protest accompanied the payment of additional search fees.

INTERNATIONAL SEARCH REPORT

Information on patent family members

International application No.

PCT/US 93/11332

PCI/US 93/11332

Patent document cited in search report	Publication date	Patent family member(s)	Publication date	
US-A-4057636	08-11-77	GB-A-	1489879	26-10-77
		AT-B-	346357	10-11-78
		AU-A-	8712775	09-06-77
		BE-A-	836885	21-06-76
		CA-A-	1067083	27-11-79
		CH-A-	618429	31-07-80
		DE-A, C	2557438	24-06-76
		DE-C-	2560633	08-09-88
		FR-A, B	2294703	16-07-76
		JP-C-	1305959	13-03-86
		JP-A-	51086474	29-07-76
		JP-B-	60028819	06-07-85
		LU-A-	74071	11-11-76
		NL-A-	7514852	22-06-76
		SE-B-	424637	02-08-82
		SE-A-	7514153	21-06-76
		US-E-	RE31244	17-05-83

US-A-5006523	09-04-91	NONE		

EP-A-0354553	14-02-90	AU-B-	620424	20-02-92
		AU-A-	3895989	15-02-90
		AU-B-	640844	02-09-93
		AU-A-	9007591	13-02-92
		JP-A-	2091057	30-03-90
		US-A-	5011837	30-04-91
		US-A-	5278169	11-01-94

EP-A-0381504	08-08-90	AU-B-	623217	07-05-92
		AU-A-	4897790	09-08-90
		CA-A-	2009074	03-08-90
		JP-A-	2235868	18-09-90
		US-A-	5264445	23-11-93

DE-A-3005786	28-08-80	JP-A-	56008357	28-01-81
		JP-C-	1313277	28-04-86
		JP-A-	55111466	28-08-80
		JP-B-	60016940	30-04-85
		CA-A-	1145751	03-05-83
		CA-A-	1158648	13-12-83

INTERNATIONAL SEARCH REPORT

Information on patent family members

International application No.

PCT/US 93/11332

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
DE-A-3005786		CH-A- 641772	15-03-84
		FR-A, B 2453155	31-10-80
		GB-A, B 2046736	19-11-80
		GB-A, B 2107306	27-04-83
		NL-A- 8000869	19-08-80
		SE-A- 8001216	17-08-80
		SE-A- 8403871	26-07-84
		US-A- 4287346	01-09-81
		US-A- 4327217	27-04-82
		US-A- 4363921	14-12-82
		US-A- 4396764	02-08-83
		US-A- 4426521	17-01-84
